TMIGD1: A Technology for Drug Development (G388364)

Target Name: TMIGD1

NCBI ID: G388364

TMIGD1

TMIGD1: A Technology for Drug Development

TMIGD1 (Tissue Magnetoresistance Imaging guided drug) is a technology that has the potential to revolutionize drug development by providing a new level of accuracy and speed in the identification of drug targets and biomarkers. TMIGD1 is a drug target (or biomarker) that is designed to be used in clinical trials to select for potential drugs, by using a novel imaging technique that is able to detect the presence of drugs in the body and track their movement.

TMIGD1 is a protein that is expressed in many different tissues in the body, including the brain, heart, and kidneys. It is made up of four subunits, which are encoded by the genes E1, E2, E3, and E4. The subunits of TMIGD1 are composed of a protein core and a cytoplasmic tail, which is responsible for the protein's stability and localization to different tissues.

One of the key advantages of TMIGD1 is its ability to select for drugs based on their ability to interact with the protein. This is because TMIGD1 is able to detect the presence of drugs in the body, even if they are at low concentrations. This is important because it allows researchers to identify drugs that are able to interact with TMIGD1 and potentially enhance the effects of those drugs.

In addition to its ability to select for drugs, TMIGD1 is also used as a biomarker to track the movement of drugs in the body. This is done by using a technique called Tracker Technology, which allows researchers to visualize the movement of drugs in real-time, using a magnetic field. This allows researchers to see where drugs are being taken up into the body, and where they are being eliminated.

TMIGD1 has the potential to revolutionize drug development by providing a new level of accuracy and speed in the identification of drug targets and biomarkers. By using its ability to select for drugs based on their ability to interact with the protein, and as a biomarker to track the movement of drugs in the body, TMIGD1 has the potential to greatly improve the efficiency and effectiveness of drug development.

Protein Name: Transmembrane And Immunoglobulin Domain Containing 1

Functions: May control cell-cell adhesion, cell migration and proliferation, cell morphology, and protects renal epithelial cells from oxidative cell injury to promote cell survival

The "TMIGD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMIGD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets